| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Parschauer Karah Herdman | EVP and Chief Legal Officer | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO | /s/ Karah Parschauer | 03 Mar 2026 | 0001677455 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RARE | Common Stock | Award | $0 | +11,137 | +15% | $0.000000 | 84,408 | 01 Mar 2026 | Direct | F1 |
| transaction | RARE | Common Stock | Sale | $185,478 | -8,135 | -9.6% | $22.80 | 76,346 | 02 Mar 2026 | Direct | F2, F3, F4, F5 |
| Id | Content |
|---|---|
| F1 | Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics. |
| F2 | Represents shares sold to pay required tax withholdings due to the vesting of RSUs. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range |
| F4 | Includes 73 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on October 31, 2025 |
| F5 | Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |